A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
A phase 1/2 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.
Overview
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC is a phase 1/2 interventional study registered as NCT07206498 by Wayshine Biopharm, Inc., with 48 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-10-14. Interventions recorded: Osimertinib (Tagrisso®), WSD0922-FU. Conditions listed: Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.